[Hypercoagulability and cerebral infarction].
D001241:Aspirin / Q000627:therapeutic use; D001777:Blood Coagulation; D001779:Blood Coagulation Factors / Q000502:physiology; D001792:Blood Platelets / Q000187:drug effects / Q000502:physiology; D002544:Cerebral Infarction / Q000503:physiopathology* / Q000517:prevention & control; D002986:Clinical Trials as Topic; D004176:Dipyridamole / Q000627:therapeutic use; D006023:Glycoproteins / Q000097:blood; D006801:Humans; D010974:Platelet Aggregation / Q000187:drug effects; D013442:Sulfinpyrazone / Q000627:therapeutic use; D013468:Suloctidil / Q000627:therapeutic use; D013931:Thromboxanes / Q000097:blood; D014841:von Willebrand Factor / Q000502:physiology
D001779:Blood Coagulation Factors; D006023:Glycoproteins; D013931:Thromboxanes; D014841:von Willebrand Factor; D004176:Dipyridamole; D001241:Aspirin; D013442:Sulfinpyrazone; D013468:Suloctidil